Hydrazinecarbothioamides represent a privileged class of pharmacophores in pharmacology, thanks to an impressive number of derivatives that exhibit outstanding antimicrobial, anticancer and antifungal properties [1]. The presence of electron donor atoms such as N(nitrogen) and S(sulfur) substantially widen the spectrum of use. In the framework of theoretical studies on the structure of biologically active compounds with valuable properties were highlighted following common structural elements such as substitution of a hydrogen atom from the nitrogen atom (N) with the benzene ring, the introduction of electron-donating substituents, the presence of the atom of sulfur and condensation with carbonyl compounds from the pyridine series but also with benzaldehyde derivatives [2]. At the initial stage called "ab initio", all compounds selected for synthesis were evaluated by the computational method of correspondence to Lipinski's rule [3]. Results suggest that the evaluated compounds fall within the theoretical parameters. A simulation of their interaction with an anticancer biological target such as RR (ribonucleotide reductase, the protein responsible for the synthesis of cellular DNA) was performed. Hydrazinecarbothioamides condensed with carbonyl compounds were highlighted as having a powerful anticancer potential due to their substantially lower binding energy than of free hydrazinecarbothioamides. A new series of N-(methylphenyl)hydrazinecarbothioamides were obtained starting from corresponding methylanilines. These compounds were subsequently condensed with aromatic carbonyl compounds and heterocyclics. The research of the anticancer properties was carried out in vitro, on a series of cancer cell lines: cervical adenocarcinoma (HeLa), human pancreatic adenocarcinoma (BxPC-3), muscle tissue myosarcoma (RD) and human leukemia (HL-60). The toxicity of the compounds was evaluated on the normal renal epithelial cell line (MDCK). The results of the in vitro evaluation of anticancer properties revealed that N-(2,4-dimethylphenyl)-2-(2-hydroxybenzylidene)-hydrazinecarbothioamide inhibits the proliferation of HL-60 cancer cells in proportion of 90-98%, at both concentrations of 10 μM and 0.1 μM. This compound exhibits a higher activity than DOX (doxorubicin), drug used in cancer chemotherapy.